Ulipristal Acetate Prior to Surgery for Endometriosis

Selective progesterone receptor modulators may have a role in the treatment of endometriosis. The aim of this report is to review the effect of ulipristal acetate (UPA) on endometriosis lesions and symptoms in women treated prior to surgery. A pathology review of eutopic endometrium and endometriotic lesions was conducted by two gynecologic pathologists. The main outcome measures reported are pain reduction, amenorrhea, and pathologic progesterone receptor modulator-associated endometrial changes (PAECs). Overall, fifteen women with endometriosis received UPA over a 27-month study period. UPA was administered in an intermittent fashion in the majority of patients while 27% of patients had continuous treatment, between 6 and 24 months. Eleven (73%) patients reported amenorrhea on UPA and 11 (92%) of 12 patients with pain reported pain reduction or resolution. Fourteen patients (93%) proceeded with surgical management. Thirteen (93%) patients underwent excision of suspected endometriosis at surgery. Twelve cases (86%) had concurrent eutopic endometrium specimens and PAEC was identified in 58% (n = 7). Among the 14 cases that underwent surgery, a total of 49 extraovarian sites were sampled. Endometriosis was definitively identified in 31 (63%) of these sites. Three cases (21%) showed morphologic features similar to PAEC within foci of endometriosis. All cases of PAEC-like features in endometriosis also had PAEC in the endometrium. These patients had all noted pain reduction and amenorrhea preoperatively. In conclusion, PAECs may be found in endometriosis lesions in patients treated with UPA. Further prospective investigation is required to evaluate the efficacy and safety of SPRMs in women with endometriosis. Similar content being viewed by others

Donnez J, Vazquez F, Tomaszewski J, Nouri K, Bouchard P, Fauser BC, et al. Long-term treatment of uterine fibroids with ulipristal acetate. Fertil Steril. 2014;101(6):1565–73.e1–18. https://doi.org/10.1016/j.fertnstert.2014.02.008. Donnez J, Tomaszewski J, Vazquez F, Bouchard P, Lemieszczuk B, Baro F, et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med. 2012;366(5):421–32. https://doi.org/10.1056/NEJMoa1103180. Donnez J, Tatarchuk TF, Bouchard P, Puscasiu L, Zakharenko NF, Ivanova T, et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med. 2012;366(5):409–20. https://doi.org/10.1056/NEJMoa1103182. Allergan. Fibristal monograph. 2016. Canada H. Fibristal 2016. Available from: https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailTwo.php?linkID=SBD00217. Accessed 8 July 2018. Bulun S. Ulipristal acetate for treatment of endometriosis-related pelvic pain. [Phase IV clinical trial]. In press Active. Wagenfeld A, Bone W, Schwede W, Fritsch M, Fischer OM, Moeller C. BAY 1002670: a novel, highly potent and selective progesterone receptor modulator for gynaecological therapies. Hum Reprod. 2013;28(8):2253–64. https://doi.org/10.1093/humrep/det247. Bayer. Assess safety and efficacy of vilaprisan in subjects with endometriosis (VILLENDO). [Phase II clinical trial]. In press Active. Tosti C, Biscione A, Morgante G, Bifulco G, Luisi S, Petraglia F. Hormonal therapy for endometriosis: from molecular research to bedside. Eur J Obstet Gynecol Reprod Biol. 2017;209:61–6. https://doi.org/10.1016/j.ejogrb.2016.05.032. Fu J, Song H, Zhou M, Zhu H, Wang Y, Chen H, et al. Progesterone receptor modulators for endometriosis. Cochrane Database Syst Rev. 2017;7:CD009881. https://doi.org/10.1002/14651858.CD009881.pub2. De Milliano I, Van Hattum D, Ket JCF, Huirne JAF, Hehenkamp WJK. Endometrial changes during ulipristal acetate use: a systematic review. Eur J Obstet Gynecol Reprod Biol. 2017;214:56–64. https://doi.org/10.1016/j.ejogrb.2017.04.042. Bressler LH, Bernardi LA, Snyder MA, Wei JJ, Bulun S. Treatment of endometriosis-related chronic pelvic pain with ulipristal acetate and associated endometrial changes. HSOA J Reprod Med Gynaecol Obstet. 2017;2. https://doi.org/10.24966/rmgo-2574/100008. Williams AR, Bergeron C, Barlow DH, Ferenczy A. Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate. Int J Gynecol Pathol. 2012;31(6):556–69. https://doi.org/10.1097/PGP.0b013e318251035b. Nogales FF, Crespo-Lora V, Cruz-Viruel N, Chamorro-Santos C, Bergeron C. Endometrial changes in surgical specimens of perimenopausal patients treated with ulipristal acetate for uterine leiomyomas. Int J Gynecol Pathol. 2017. https://doi.org/10.1097/pgp.0000000000000450. Conway F, Morosetti G, Camilli S, Martire FG, Sorrenti G, Piccione E, et al. Ulipristal acetate therapy increases ultrasound features of adenomyosis: a good treatment given in an erroneous diagnosis of uterine fibroids. Gynecol Endocrinol. 2019;35(3):207–10. https://doi.org/10.1080/09513590.2018.1505846. Bateman J, Bougie O, Singh S, Islam S. Histomorphological changes in endometriosis in a patient treated with ulipristal: a case report. Pathol Res Pract. 2017;213(1):79–81. https://doi.org/10.1016/j.prp.2016.10.010. Evaluation of therapeutic effect and safety of mifepristone in the treatment of adenomyosis. https://ClinicalTrials.gov/show/NCT03520439. Bulun SE. Endometriosis. N Engl J Med. 2009;360(3):268–79. https://doi.org/10.1056/NEJMra0804690. Donnez J, Arriagada P, Marciniak M, Larrey D. Liver safety parameters of ulipristal acetate for the treatment of uterine fibroids: a comprehensive review of the clinical development program. Expert Opin Drug Saf. 2018;17(12):1225–32. https://doi.org/10.1080/14740338.2018.1550070. Singh SS, Suen MW. Surgery for endometriosis: beyond medical therapies. Fertil Steril. 2017;107(3):549–54. https://doi.org/10.1016/j.fertnstert.2017.01.001. Guo SW, Groothuis PG. Is it time for a paradigm shift in drug research and development in endometriosis/adenomyosis? Hum Reprod Update. 2018;24(5):577–98. https://doi.org/10.1093/humupd/dmy020. Acknowledgments The authors would like to thank The Ottawa Hospital Minimally Invasive Gynecology Group staff for helping facilitate the completion of this project (Ms. Suzannah Wojcik BHScH, Dr. Teresa Flaxman PhD, and Ms. Erica Nichols RN). Author information Authors and Affiliations Contributions Dr. S. Singh developed the concept for this work and all authors contributed to data acquisition, interpretation, manuscript development, and final review. Corresponding author Ethics declarations Conflict of Interest S.S.S. reports other from Allergan, other from AbbVie, other from Bayer, personal fees from Allergan, personal fees from AbbVie, personal fees from Bayer, personal fees from Hologic, and personal fees from Cooper Surgical, outside the submitted work. D.E. has no conflicts of interest. S.M. has no conflicts of interest. M.S. has no conflicts of interest. S. S. has no conflicts of interest. Rights and permissions About this article Cite this article Singh, S.S., Evans, D., McDonald, S. et al. Ulipristal Acetate Prior to Surgery for Endometriosis. Reprod. Sci. 27, 1707–1714 (2020). https://doi.org/10.1007/s43032-020-00146-1 Received: Accepted: Published: Version of record: Issue date: DOI: https://doi.org/10.1007/s43032-020-00146-1